Harbin Medisan Pharmaceutical Co., Ltd.
SZSE:002900.SZ
12.44 (CNY) • At close October 26, 2023
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 1,186.786 | 1,028.414 | 945.799 | 1,338.883 | 2,102.061 | 2,172.516 | 1,148.83 | 760.872 | 722.017 | 681.521 | 601.23 | 491.17 |
| Kosten van de omzet
| 476.38 | 365.572 | 309.385 | 491.301 | 509.922 | 351.967 | 296.701 | 290.049 | 275.855 | 287.44 | 280.716 | 268.529 |
| Brutowinst
| 710.406 | 662.841 | 636.415 | 847.582 | 1,592.14 | 1,820.549 | 852.129 | 470.823 | 446.161 | 394.082 | 320.514 | 222.641 |
| Brutowinstmarge
| 0.599 | 0.645 | 0.673 | 0.633 | 0.757 | 0.838 | 0.742 | 0.619 | 0.618 | 0.578 | 0.533 | 0.453 |
| Onderzoek- en ontwikkelingskosten
| 112.806 | 89.269 | 99.922 | 112.019 | 112.448 | 79.006 | 69.352 | 49.036 | 54.016 | 50.61 | 30.903 | 20.816 |
| Algemene en administratieve kosten
| 36.671 | 25.857 | 101.193 | 80.518 | 90.884 | 19.915 | 15.036 | 11.678 | 15.665 | 14.296 | 98.266 | 62.76 |
| Verkoop- en marketingkosten
| 421.797 | 453.909 | 517.573 | 605.066 | 1,153.618 | 1,436.069 | 465.978 | 132.769 | 127.094 | 105.702 | 70.053 | 40.847 |
| Verkoop-, algemene en administratieve kosten
| 458.468 | 479.766 | 618.766 | 685.584 | 1,244.502 | 1,455.984 | 481.014 | 144.447 | 142.759 | 119.998 | 168.319 | 103.607 |
| Overige kosten
| 2.353 | 110.517 | 46.548 | -11.13 | 27.156 | -1.899 | 0.33 | 17.374 | 11.955 | 19.955 | 2.113 | -6.557 |
| Bedrijfskosten
| 693.357 | 679.551 | 765.236 | 786.473 | 1,384.106 | 1,604.947 | 619.476 | 264.476 | 263.448 | 226.333 | 174.141 | 108.499 |
| Bedrijfsresultaat
| 79.022 | 57.601 | 454.805 | 84.218 | 228.809 | 250.996 | 252.708 | 197.752 | 186.937 | 163.57 | 121.413 | 103.037 |
| Bedrijfsresultaat ratio
| 0.067 | 0.056 | 0.481 | 0.063 | 0.109 | 0.116 | 0.22 | 0.26 | 0.259 | 0.24 | 0.202 | 0.21 |
| Totaal overige inkomsten en kosten netto
| 2.353 | -17.531 | -1.95 | -51.061 | -0.586 | 33.495 | 20.384 | 2.778 | 15.271 | 6.747 | -24.199 | -19.527 |
| Inkomen voor belasting
| 81.374 | 40.07 | 452.856 | 33.157 | 228.223 | 249.097 | 253.037 | 209.126 | 197.984 | 174.496 | 122.175 | 94.615 |
| Inkomen voor belasting ratio
| 0.069 | 0.039 | 0.479 | 0.025 | 0.109 | 0.115 | 0.22 | 0.275 | 0.274 | 0.256 | 0.203 | 0.193 |
| Belastingkosten
| 11.295 | 13.567 | 103.178 | 6.524 | 54.363 | 44.711 | 71.962 | 33.943 | 31.683 | 27.512 | 17.877 | 14.277 |
| Nettowinst
| 73.663 | 30.207 | 350.951 | 29.325 | 177.184 | 205.813 | 181.076 | 175.183 | 166.301 | 146.984 | 104.394 | 82.717 |
| Nettowinstmarge
| 0.062 | 0.029 | 0.371 | 0.022 | 0.084 | 0.095 | 0.158 | 0.23 | 0.23 | 0.216 | 0.174 | 0.168 |
| WPA (Winst Per Aandeel)
| 0.24 | 0.095 | 1.13 | 0.095 | 0.57 | 0.65 | 0.71 | 0.74 | 0.7 | 0.63 | 0.47 | 5.3 |
| Verwaterde WPA
| 0.24 | 0.095 | 1.13 | 0.095 | 0.57 | 0.65 | 0.71 | 0.74 | 0.7 | 0.63 | 0.47 | 5.3 |
| EBITDA
| 198.569 | 164.169 | 577.688 | 164.165 | 304.587 | 329.67 | 333.89 | 278.151 | 241.918 | 217.395 | 166.593 | 122.628 |
| EBITDA ratio
| 0.167 | 0.16 | 0.611 | 0.123 | 0.145 | 0.152 | 0.291 | 0.366 | 0.335 | 0.319 | 0.277 | 0.25 |